A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers.

Jakob JA Kies MS Glisson BS Kupferman ME Liu DD Lee JJ El-Naggar AK Gonzalez-Angulo AM Blumenschein GR; Head Neck. 2014 Mar 2 .

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.

Bucheit, A. D.,Syklawer, E.,Jakob, J. A.,Bassett, R. L.,Curry, J. L.,Gershenwald, J. E.,Kim, K. B.,Hwu, P.,Lazar, A. J.,Davies, M. A.; Cancer. 2013 Aug 6.

Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.

Joseph RW Eckel-Passow JE Sharma R Liu P Parker A Jakob J Buchbinder E Bassett RL Davies MA Hwu P Atkins MB Sullivan RJ; J Immunother. 2012 Nov-Dec .